【】

The Food and Drug Administration has approved the first pill embedded with a sensor that can alert a patient’s physician or caregiver when it’s been ingested, the agency announced on Monday.
The Japanese drug maker Otsuka Pharmaceutical won the approval for an upgraded version of Abilify, the antipsychotic drug first approved 15 years ago to treat schizophrenia, bipolar disorder, and depression. Otsuka collaborated with Proteus Digital Health, the Silicon Valley company that designed the futuristic sensor technology.
SEE ALSO:Big Pharma’s big push to get patients to take their medsThe new product, which will be sold as Abilify MyCite, can be swallowed just like any other pill. When that happens, the ingestible sensor inside it sends a message to a patch worn by the patient, which then transmits the information to a mobile app that the patient can monitor. If a patient opts to allow it, the patient’s caregivers and doctor can access the data online, too.
The FDA’s decision Monday comes a year and a half after the agency rejected the product. At the time, the agency said it needed more information about how the product is used and how human error could create risks. Monday’s hard-won approval could come as a big boost for Otsuka, which had lost market share after Abilify went generic but will now have a way to make the product stand out.
Forgetfulness and cloudy thinking can be symptoms of the mental health conditions that Abilify is approved to treat, and patients with mental illness are known to struggle to take medication consistently. But the new product will also be labeled with a caveat: There’s no evidence that the technology can help patients take their medication as prescribed.
The landmark approval is the latest in an expansive rethinking of what constitutes a treatment. In September, the FDA approved the first mobile app to treat certain substance use disorders, developed by the Boston company Pear Therapeutics.
Featured Video For You
This biosensor allows doctors to monitor a patient's vitals from anywhere
TopicsHealth
相关文章
- Fiji's men's rugby sevens team has made history by defeating Great Britain and claiming the country'2025-04-26
- 成長不規劃,來年差距大!2023斯坦星球全年賽事規劃請查收_足球 - 世界杯,歐洲杯,天下體育 ,足球,世界杯,籃球,羽球 ,乒乓球 ,球類, 棒球 ( 賽事,機器人 )www.ty42.com 日期:22025-04-26
現役球員誰能突破3000萬大關?四位球星或存在可能,詹姆斯很難被超越(詹姆斯擅長三分嗎)
現役球員誰能突破3000萬大關 ?四位球星或存在可能 ,詹姆斯很難被超越詹姆斯擅長三分嗎)_籃球 - 世界杯 ,歐洲杯,天下體育,足球 ,世界杯,籃球 ,羽球,乒乓球 ,球類, 棒球 ( 球員,大關www.ty2025-04-26- 體壇快訊2023.2.3)_羽毛球 - 世界杯,歐洲杯 ,天下體育,足球 ,世界杯 ,籃球 ,羽球,乒乓球 ,球類, 棒球 ( 北京時間,教練員 )www.ty42.com 日期:2023-02-03 00:2025-04-26
Satisfy your Olympics withdrawals with Nike's latest app
Following in the footsteps of last year's successful launch of Nike's Tech Book is back in its secon2025-04-26- 體育·國際足球)“紅”“藍”爭冠格局不變——2022-2023賽季英超前瞻_足球 - 世界杯,歐洲杯,天下體育 ,足球,世界杯 ,籃球 ,羽球 ,乒乓球,球類, 棒球 ( 利物浦,蘭德 )www.ty42.2025-04-26
最新评论